Exosomal EPHA2 transfers metastatic potential by stabilizing TGF-βRI and activating the TGF-β/SMAD3 signaling pathway in breast cancer
Authors:
Open Access
- 23 February 2026
- journal article
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- p. 1-28
Abstract
Objective: Intratumoral heterogeneity refers to the presence of distinct subpopulations of cancer cells within a single tumor, which exhibits variations in phenotypic traits, such as proliferation rate, drug sensitivity, and metastatic potential. Dynamic interactions among heterogeneous cell populations have a critical role in tumor progression. Increasing evidence underscores the importance of intercellular communication among heterogeneous cancer cell subpopulations in driving malignancy. However, the molecular mechanisms governing such cancer cell-to-cancer cell interactions are poorly understood. Methods: Exosomes were isolated from highly metastatic breast cancer cells (HM-BCCs) and low metastatic breast cancer cells (LM-BCCs). The role of exosome-mediated intercellular communication on metastatic behavior was assessed using wound healing and Transwell assays. Gene knockdown and overexpression strategies, small-molecule inhibitors, and xenograft mouse models were used to elucidate the role of exosomal EPHA2. Results: Exosomes derived from HM-BCCs considerably enhanced the migratory and invasive capabilities of LM-BCCs in vitro and increased the metastatic potential in vivo. Mechanistically, EPHA2 was identified as a key protein enriched in exosomes from HM-BCCs and was shown to be transferred to LM-BCCs by these vesicles. Exosomal EPHA2 promoted epithelial-to-mesenchymal transition in LM-BCCs when internalized by stabilizing TGF-βRI and activating the transforming growth factor-β/mothers against decapentaplegic homolog 3 (TGF-β/SMAD3) signaling pathway, thereby facilitating the acquisition of a metastatic phenotype. Conclusions: The results underscore the pivotal function of exosomal EPHA2 in mediating the transfer of metastatic potential among heterogeneous breast cancer cell populations. Targeting the EPHA2-TGF-βRI signaling axis may provide a novel therapeutic approach for preventing or limiting breast cancer metastasis.Keywords
This publication has 35 references indexed in Scilit:
- LDHA‐mediated M2‐type macrophage polarization via tumor‐derived exosomal EPHA2 promotes renal cell carcinoma progressionMolecular Carcinogenesis, 2024
- Exploring the potential of EphA2 receptor signaling pathway: a comprehensive review in cancer treatmentMolecular Biology Reports, 2024
- Exosomal EphA2 promotes tumor metastasis of triple-negative breast cancer by damaging endothelial barrierClinical & Experimental Metastasis, 2022
- Exosome-mediated remodeling of the tumor microenvironment: From local to distant intercellular communicationCancer Letters, 2022
- EGFR‐rich extracellular vesicles derived from highly metastatic nasopharyngeal carcinoma cells accelerate tumour metastasis through PI3K/AKT pathway‐suppressed ROSJournal of Extracellular Vesicles, 2020
- Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLCCell Reports, 2020
- Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targetsSeminars in Cancer Biology, 2020
- Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liverNature Cell Biology, 2015
- Cell adhesion and EGFR activation regulate EphA2 expression in cancerCellular Signalling, 2010
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA BreaksCell, 2010